![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Campos-Barros, H Meinhold, M Stula, F Muller, R Kohler, M Eravci, O Putzien and A Baumgartner
Psychiatrische Klinik and Poliklinik (Universitatsklinikum Rudolf- Virchow, Berlin, Germany.
The effect of the antidepressant desipramine (DMI) on the activities of the three iodothyronine deiodinase isoenzymes involved in the central metabolism of thyroid hormones were investigated in 11 brain regions and 3 peripheral tissues in the rat. The investigations were carried out at three different times during the light/dark cycle: 5 A.M., 1 P.M. and 11 P.M. Interest is focused on changes in the two enzymes that catalyze: i) the 5'deiodination of T4 to the biologically active T3, i.e., type II 5'deiodinase (5'D-II), and ii) the 5 (or inner-ring) deiodination of T3 to the biologically inactive 3,3'T2, i.e., type III 5 deiodinase (5D-III). Fourteen days' treatment with 20 mg/kg DMI, but not with 5 mg/kg DMI, induced significant increases in 5'D-II in eight different areas of the CNS. The regions affected were identical to those that receive noradrenergic input from the locus coeruleus. Even control animals showed a circadian rhythm of 5'D-II activity in some brain regions, and the effects of DMI also depended on the time of death within the 24-hr rhythm. 5D-III was not affected. Serum T4 were lower after administration of DMI, most probably because of enhanced tissue uptake of T4. This is in line with the corresponding finding in depressed patients, indicating that similar changes in both central and peripheral thyroid hormone metabolism may occur after antidepressant pharmacotherapy in both humans and rats. These data support the hypothesis that interactions with the CNS metabolism of the thyroid hormones may be involved in the mechanisms of action of DMI.
This article has been cited by other articles:
|
|
 |
|
  J. P Brouwer, B. C Appelhof, R. P Peeters, W. J G Hoogendijk, J. Huyser, A. H Schene, J. G P Tijssen, R. Van Dyck, T. J Visser, W. M Wiersinga, et al. Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. Eur. J. Endocrinol., June 1, 2006; 154(6): 819 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Gendall, P. R. Joyce, R. T. Mulder, and S. E. Luty Thyroid Indices and Response to Fluoxetine and Nortriptyline in Major Depression J Psychopharmacol, December 1, 2003; 17(4): 431 - 437. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Eravci, G. Pinna, H. Meinhold, and A. Baumgartner Effects of Pharmacological and Nonpharmacological Treatments on Thyroid Hormone Metabolism and Concentrations in Rat Brain Endocrinology, March 1, 2000; 141(3): 1027 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Campos-Barros, L. L. Amma, J. S. Faris, R. Shailam, M. W. Kelley, and D. Forrest Type 2 iodothyronine deiodinase expression in the cochlea before the onset of hearing PNAS, February 1, 2000; 97(3): 1287 - 1292. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
